Literature DB >> 27915325

Possible Role of Sildenafil Citrate in the Recurrence of Neovascularization in Laser-regressed Aggressive Posterior ROP.

Chaitra Jayadev1, Phanibhushan Ramasastry, Alia Gul, Anand Vinekar.   

Abstract

BACKGROUND: Systemic diseases and their treatment influence aggressive posterior retinopathy of prematurity. CASE CHARACTERISTICS: A premature infant with aggressive posterior retinopathy of prematurity underwent laser treatment with a favourable outcome. She was started on oral sidenafil citrate for pulmonary hypertension. Ten days later she developed neovascularization within the lasered retina. INTERVENTION/OUTCOME: Considering the possible role of sildenafil in this unusual development, the drug was withdrawn resulting in regression of the neovascularization. MESSAGE: The clinician should be aware of this retinal adverse effect of sildanefil in neonates with aggressive posterior retinopathy of prematurity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27915325

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  4 in total

Review 1.  Controversies in the identification and management of acute pulmonary hypertension in preterm neonates.

Authors:  Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara
Journal:  Pediatr Res       Date:  2017-10-04       Impact factor: 3.756

Review 2.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

3.  Association of Cardiovascular Disease with Retinopathy of Prematurity.

Authors:  Faizah Bhatti; Yinxi Yu; Gui-Shuang Ying; Lauren A Tomlinson; Gil Binenbaum
Journal:  Ophthalmic Epidemiol       Date:  2022-02-09

Review 4.  Visual Side Effects Linked to Sildenafil Consumption: An Update.

Authors:  Eva Ausó; Violeta Gómez-Vicente; Gema Esquiva
Journal:  Biomedicines       Date:  2021-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.